Owlstone Medical’s disease breathalyzer, ReCIVA, to feature in Tomorrow’s World gallery at the Science Museum, London

Published on 22 Aug 17, under Press releases

Recognizes potential of the breath biopsy platform to transform diagnostics

ReCIVA Breath Sampler will be on display from Friday August 18 th, 2017

Cambridge, UK, August 22nd, 2017: Owlstone Medical, a diagnostics company, today announced that its disease breathalyzer, ReCIVA™ has been selected to feature in the Tomorrow’s World gallery at the Science Museum , London. The exhibition aims to inspire visitors with award-winning, cutting-edge scientific advances such as advanced surgical robotics, space suits and avalanche analysis technology. ReCIVA was selected to feature based on its potential to revolutionize healthcare and bring real benefits to patients, and will be on display from Friday August 18th, 2017.

Owlstone Medical’s CE-marked ReCIVA Breath Sampler forms part of the Company’s Breath Biopsy® platform, which analyzes biomarkers from breath to diagnose disease. ReCIVA is used to collect samples of breath from a patient, completely non-invasively, and analyze them with high sensitivity and selectivity.

Each exhaled breath contains a rich spectrum of Volatile Organic Compounds (VOCs) produced by the body’s metabolism that relate directly to disease activity. When analyzed, this information can enable early diagnosis and provide important insights for patient stratification, helping to ensure that the right therapy is given to the right patient at the right time, to improve clinical outcomes and reduce healthcare costs.

Billy Boyle, co-founder and CEO at Owlstone Medical commented: “Our Breath Biopsy platform presents a new approach to detect disease earlier and make better treatment decisions for patients. The ReCIVA Breath Sampler is a reliable and reproducible way to capture VOC biomarkers in breath samples, which can be sent to Owlstone Medical’s clinical laboratory in Cambridge for analysis. The technology is already in use in over 60 research and clinical labs globally, and we are honored that it has been selected to feature in the Science Museum’s Tomorrow’s World gallery.”

The Science Museum is part of the Science Museum Group, open seven days a week, 10.00 - 18.00

MORE INFORMATION

ENDS

Notes to Editors

For high resolution images, contact sarah.jeffery@zymecommunications.com

ReCIVA at the Science Museum

ReCIVA at Science Museum

Owlstone Medical’s ReCIVA Breath Sampler on display in Tomorrow’s World gallery at the Science Museum, London For a high resolution images please contact sarah.jeffery@zymecommunications.com

Videos are available at: https://www.owlstonemedical.com/about/events/reciva-science-museum/

Media contact

For more information please contact:
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0)7771 730919

About Owlstone Medical

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive early detection and precision medicine for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.Owlstone Medical’s Breath Biopsy® platform is a new diagnostic modality capable of detecting disease biomarkers in breath. The award winning ReCIVA Breath Sampler ensures reliable collection of breath samples. VOC (Volatile organic compound) biomarkers present in breath are analyzed with high sensitivity and selectivity using proven microchip chemical sensor technology (Field Asymmetric Ion Mobility Spectrometry, FAIMS).The Breath Biopsy platform has the potential to revolutionize early detection and precision medicine, with applications in cancer and a wide range of other conditions. Breath Biopsy enables disease to be detected earlier, when treatments are more effective and more lives can be saved. By identifying patients most likely to respond to a particular therapy, Breath Biopsy can also ensure that the right therapy is given to the right patient at the right time, helping to reduce healthcare costs.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also provides Breath Biopsy products and services to academic, clinical and pharmaceutical partners who want to develop breath based biomarkers for their own applications.Owlstone Inc was founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge, and is a profitable business selling FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialize FAIMS in medical applications.Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK.

Get in touch with our team today for additional product and pricing information

request pricing